151 related articles for article (PubMed ID: 37178059)
41. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma.
Durandy A; Kracker S
Blood; 2020 Feb; 135(9):638-643. PubMed ID: 31942637
[TBL] [Abstract][Full Text] [Related]
42. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
43. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.
Lucas CL; Kuehn HS; Zhao F; Niemela JE; Deenick EK; Palendira U; Avery DT; Moens L; Cannons JL; Biancalana M; Stoddard J; Ouyang W; Frucht DM; Rao VK; Atkinson TP; Agharahimi A; Hussey AA; Folio LR; Olivier KN; Fleisher TA; Pittaluga S; Holland SM; Cohen JI; Oliveira JB; Tangye SG; Schwartzberg PL; Lenardo MJ; Uzel G
Nat Immunol; 2014 Jan; 15(1):88-97. PubMed ID: 24165795
[TBL] [Abstract][Full Text] [Related]
44. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
Lucas CL; Zhang Y; Venida A; Wang Y; Hughes J; McElwee J; Butrick M; Matthews H; Price S; Biancalana M; Wang X; Richards M; Pozos T; Barlan I; Ozen A; Rao VK; Su HC; Lenardo MJ
J Exp Med; 2014 Dec; 211(13):2537-47. PubMed ID: 25488983
[TBL] [Abstract][Full Text] [Related]
45. Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Thauland TJ; Pellerin L; Ohgami RS; Bacchetta R; Butte MJ
Front Immunol; 2019; 10():753. PubMed ID: 31031754
[TBL] [Abstract][Full Text] [Related]
46. Cellular Mechanisms Underlying B Cell Abnormalities in Patients With Gain-of-Function Mutations in the
Wang W; Min Q; Lai N; Csomos K; Wang Y; Liu L; Meng X; Sun J; Hou J; Ying W; Zhou Q; Sun B; Hui X; Ujhazi B; Gordon S; Buchbinder D; Schuetz C; Butte M; Walter JE; Wang X; Wang JY
Front Immunol; 2022; 13():890073. PubMed ID: 35799777
[TBL] [Abstract][Full Text] [Related]
47. Autoimmune Cytopenia as an Early and Initial Presenting Manifestation in Activated PI3 Kinase Delta Syndrome: Case Report and Review.
Schworer SA; Francis OL; Johnson SM; Smith BD; Gold SH; Smitherman AB; Wu EY
J Pediatr Hematol Oncol; 2021 Nov; 43(8):281-287. PubMed ID: 34054047
[TBL] [Abstract][Full Text] [Related]
48. A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Cansever M; Zietara N; Chiang SCC; Ozcan A; Yilmaz E; Karakukcu M; Rohlfs M; Somekh I; Canoz O; Abdulrezzak U; Bryceson Y; Klein C; Unal E; Patiroglu T
J Pediatr Hematol Oncol; 2020 Mar; 42(2):156-159. PubMed ID: 31033788
[TBL] [Abstract][Full Text] [Related]
49. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
[TBL] [Abstract][Full Text] [Related]
50. Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans.
Takeda AJ; Zhang Y; Dornan GL; Siempelkamp BD; Jenkins ML; Matthews HF; McElwee JJ; Bi W; Seeborg FO; Su HC; Burke JE; Lucas CL
J Allergy Clin Immunol; 2017 Oct; 140(4):1152-1156.e10. PubMed ID: 28414062
[No Abstract] [Full Text] [Related]
51. Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.
Carpier JM; Lucas CL
Front Immunol; 2017; 8():2005. PubMed ID: 29387064
[TBL] [Abstract][Full Text] [Related]
52. Case Report: Activating
Lu M; Gu W; Sheng Y; Wang J; Xu X
Front Immunol; 2021; 12():670312. PubMed ID: 33995405
[TBL] [Abstract][Full Text] [Related]
53. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
[TBL] [Abstract][Full Text] [Related]
54. Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.
Buchbinder D; Seppanen M; Rao VK; Uzel G; Nugent D
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e319-e322. PubMed ID: 29200144
[TBL] [Abstract][Full Text] [Related]
55. The Treatment of Activated PI3Kδ Syndrome.
Coulter TI; Cant AJ
Front Immunol; 2018; 9():2043. PubMed ID: 30245694
[TBL] [Abstract][Full Text] [Related]
56. Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs.
Jia Y; Yang Q; Wang Y; Li W; Chen X; Xu T; Tian Z; Feng M; Zhang L; Tang W; Tian N; Zhou L; Song W; Zhao X
Cell Mol Immunol; 2021 Jul; 18(7):1783-1797. PubMed ID: 32099075
[TBL] [Abstract][Full Text] [Related]
57. Resolving the polygenic aetiology of a late onset combined immune deficiency caused by NFKB1 haploinsufficiency and modified by PIK3R1 and TNFRSF13B variants.
Hargreaves CE; Dhalla F; Patel AM; de Oteyza ACG; Bateman E; Miller J; Anzilotti C; Ayers L; Grimbacher B; Patel SY
Clin Immunol; 2022 Jan; 234():108910. PubMed ID: 34922003
[TBL] [Abstract][Full Text] [Related]
58. Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects.
Jhamnani RD; Nunes-Santos CJ; Bergerson J; Rosenzweig SD
Front Immunol; 2018; 9():2172. PubMed ID: 30319630
[TBL] [Abstract][Full Text] [Related]
59. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility.
Crank MC; Grossman JK; Moir S; Pittaluga S; Buckner CM; Kardava L; Agharahimi A; Meuwissen H; Stoddard J; Niemela J; Kuehn H; Rosenzweig SD
J Clin Immunol; 2014 Apr; 34(3):272-6. PubMed ID: 24610295
[TBL] [Abstract][Full Text] [Related]
60. Concomitant
Rodriguez R; Fournier B; Cordeiro DJ; Winter S; Izawa K; Martin E; Boutboul D; Lenoir C; Fraitag S; Kracker S; Watts TH; Picard C; Bruneau J; Callebaut I; Fischer A; Neven B; Latour S
J Exp Med; 2019 Dec; 216(12):2800-2818. PubMed ID: 31537641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
